Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.

Cardiovasc Diabetol · 2024 · PMC10854040 · PMID 38331813

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Empagliflozin, on the other hand, showed a 13% risk reduction for MI relative to placebo which did not reach statistical significance, and a numerical increase in the risk of stroke in patients with T2D and ASCVD [ 1 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.